Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study

Table 3 Subgroup analysis of mPFS of advanced NSCLC patients who received combination therapy of PD-1 inhibitors and antiangiogenic drugs

Characters	mPFS(months)	HR (95% CI)	p value
Gender
Male vs. Female	8.5 vs. 4.2	0.738(0.425,1.282)	0.281
Age
< 60 vs. ≥ 60	7.9 vs. 7.6	0.931(0.592,1.464)	0.757
TNM Stage
IV vs. III	6.1 vs. 12.0	2.005(1.026,3.920)	0.042*
Histology
Adenocarcinoma vs. Squamous	5.9 vs. 9.8	1.568(0.994,2.474)	0.053
Smoke
Yes vs. No	8.0 vs. 7.6	0.865(0.551,1.358)	0.528
Brain metastasis
Yes vs. No	3.8 vs. 9.2	1.714(1.034,2.843)	0.037*
Liver metastasis
Yes vs. No	5.0 vs. 8.4	1.320(0.738,2.362)	0.350
Bone metastasis
Yes vs. No	5.9 vs. 8.5	1.802(1.118,2.902)	0.016*
Pleural effusion
Yes vs. No	4.6 vs. 8.4	1.456(0.782,2.708)	0.236
Treatment lines
1 line vs. 2 lines vs. ≥ 3 lines^a	8.0 vs. 9.4 vs. 5.5	0.755(0.297, 1.915)	0.554
1 line vs. 2 lines vs. ≥ 3 lines^a	8.0 vs. 9.4 vs. 5.5	0.659(0.410, 1.060)	0.086
PD L1 expression
Negative vs. Positive	5.8 vs. 9.2	1.041(0.664,1.633)	0.859
Negative vs. Low. vs. High^a	5.8 vs. 8.0 vs. 10.7	1.080 (0.561,2.079)	0.818
Negative vs. Low. vs. High^a	5.8 vs. 8.0 vs. 10.7	1.192 (0.597,2.381)	0.619
Gene mutation
Wild vs. all EGFR	8.0 vs. 4.4	0.567(0.318,1.010)	0.054
Wild vs. all EGFR vs. KRAS^a	6.1 vs. 4.4 vs. 9.4	0.914(0.483,1.729)	0.783
Wild vs. all EGFR vs. KRAS^a	6.1 vs. 4.4 vs. 9.4	1.656(0.800,3.432)	0.174

NSCLC Non-small cell lung cancer, mPFS Median progression-free survival, PD-1 Programmed death 1, HR Hazard rate, CI Confidence interval, Squamous Squamous cell carcinoma, PD-L1 (programmed death ligand 1) expression, negative, 0%; positive, ≥ 1%, low, 1%-49%; high, ≥ 50%. EGFR (epidermal growth factor receptor), including classical EGFR mutation and nonclassical EGFR mutation, KRAS Kirsten Rat Sarcoma Viral Oncogene Homologue
^*significance p values
^aThe last group served as a control

ISSN: 1471-2466